CN1263533A - 新型制剂 - Google Patents

新型制剂 Download PDF

Info

Publication number
CN1263533A
CN1263533A CN98807089A CN98807089A CN1263533A CN 1263533 A CN1263533 A CN 1263533A CN 98807089 A CN98807089 A CN 98807089A CN 98807089 A CN98807089 A CN 98807089A CN 1263533 A CN1263533 A CN 1263533A
Authority
CN
China
Prior art keywords
pharmaceutical composition
compound
treatment
alkyl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98807089A
Other languages
English (en)
Chinese (zh)
Inventor
J·布罗德赫德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
Astra Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1263533(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Pharmaceuticals Ltd filed Critical Astra Pharmaceuticals Ltd
Publication of CN1263533A publication Critical patent/CN1263533A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN98807089A 1997-07-11 1998-06-29 新型制剂 Pending CN1263533A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702680A SE9702680D0 (sv) 1997-07-11 1997-07-11 New formulation
SE97026801 1997-07-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2006100092846A Division CN1864696A (zh) 1997-07-11 1998-06-29 新型制剂

Publications (1)

Publication Number Publication Date
CN1263533A true CN1263533A (zh) 2000-08-16

Family

ID=20407718

Family Applications (2)

Application Number Title Priority Date Filing Date
CN98807089A Pending CN1263533A (zh) 1997-07-11 1998-06-29 新型制剂
CNA2006100092846A Pending CN1864696A (zh) 1997-07-11 1998-06-29 新型制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2006100092846A Pending CN1864696A (zh) 1997-07-11 1998-06-29 新型制剂

Country Status (35)

Country Link
US (1) US6130208A (enExample)
EP (1) EP1000079B1 (enExample)
JP (1) JP4950380B2 (enExample)
KR (1) KR100786654B1 (enExample)
CN (2) CN1263533A (enExample)
AR (1) AR013157A1 (enExample)
AT (1) ATE340801T1 (enExample)
AU (1) AU8362598A (enExample)
BR (1) BR9810703A (enExample)
CA (1) CA2295628C (enExample)
CY (1) CY1105805T1 (enExample)
CZ (1) CZ298110B6 (enExample)
DE (1) DE69836023T2 (enExample)
DK (1) DK1000079T3 (enExample)
EE (1) EE04119B1 (enExample)
ES (1) ES2273425T3 (enExample)
HU (1) HU226489B1 (enExample)
ID (1) ID24716A (enExample)
IL (2) IL133868A0 (enExample)
IS (1) IS2439B (enExample)
MY (1) MY116421A (enExample)
NO (1) NO329918B1 (enExample)
NZ (1) NZ502073A (enExample)
PL (1) PL192768B1 (enExample)
PT (1) PT1000079E (enExample)
RU (1) RU2216330C2 (enExample)
SA (1) SA98190328B1 (enExample)
SE (1) SE9702680D0 (enExample)
SI (1) SI1000079T1 (enExample)
SK (1) SK285766B6 (enExample)
TR (1) TR200000006T2 (enExample)
TW (1) TW585764B (enExample)
UA (1) UA65576C2 (enExample)
WO (1) WO1999002542A1 (enExample)
ZA (1) ZA985669B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4986281B2 (ja) * 2004-10-05 2012-07-25 旭化成ファーマ株式会社 補酵素の安定化方法およびその組成物
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
EP2471792B1 (en) 2009-08-28 2014-04-09 Daiichi Sankyo Company, Limited 3-(biaryloxy) propionic acid derivative
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
HRP20200445T1 (hr) 2009-11-11 2020-06-12 Chiesi Farmaceutici S.P.A. Metode liječenja ili prevencije tromboze u stentu
CN104666315A (zh) * 2010-12-10 2015-06-03 西格玛制药实验有限责任公司 口服活性核苷酸类似物或口服活性核苷酸类似物前药的高度稳定组合物
JP5947316B2 (ja) 2011-02-09 2016-07-06 ザ メディシンズ カンパニー 肺高血圧症を処置するための方法
DK2744424T3 (en) 2011-08-17 2018-01-22 Samuel Shiber Adaptively rotating catheter to open clogged vessels in the body
BR112015022070B1 (pt) 2013-03-09 2022-01-18 Chiesi Farmaceutici S.P.A. Uso de cangrelor
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
RU2733409C2 (ru) 2015-01-14 2020-10-01 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Фармацевтические составы, включающие кангрелор высокой чистоты, и способы их получения и применения
CN110740736A (zh) 2017-06-23 2020-01-31 奇斯药制品公司 预防体-肺动脉分流术血栓形成的方法
TWI857957B (zh) 2018-06-19 2024-10-11 德商Ｕｃｂ製藥有限公司 吡啶基及吡基-（氮）吲哚磺醯胺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (enExample) * 1973-05-17 1981-09-03
JPS5874966A (ja) * 1981-10-28 1983-05-06 Mikuni Jukogyo Kk 高圧往復動機の軸封装置
JPS5874696A (ja) * 1981-10-30 1983-05-06 株式会社　ヤトロン アデノシン三リン酸の安定化方法
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US5563122A (en) * 1991-12-09 1996-10-08 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
PL175623B1 (pl) * 1993-02-10 1999-01-29 Astra Pharma Prod N-alkilo-2-podstawione analogi ATP, sposób ich wytwarzania i kompozycja farmaceutyczna je zawierająca
NZ270077A (en) * 1993-12-14 1996-04-26 Lilly Co Eli Aqueous complexes of benzothiophenes and cyclodextrins
DE4405426A1 (de) * 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
EP0833667A4 (en) * 1995-06-07 2001-11-21 Univ California STABILIZATION OF POLYNUCLEOTIDE COMPLEXES
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
ID21635A (id) * 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku

Also Published As

Publication number Publication date
AU8362598A (en) 1999-02-08
SI1000079T1 (sl) 2007-08-31
HU226489B1 (en) 2009-03-02
IS5331A (is) 1999-12-30
RU2216330C2 (ru) 2003-11-20
TR200000006T2 (tr) 2000-07-21
CA2295628A1 (en) 1999-01-21
PT1000079E (pt) 2006-12-29
ID24716A (id) 2000-08-03
NO20000123D0 (no) 2000-01-10
IL133868A (en) 2010-05-17
DE69836023T2 (de) 2007-04-12
DK1000079T3 (da) 2006-11-20
CZ200083A3 (cs) 2000-06-14
NO20000123L (no) 2000-03-03
SE9702680D0 (sv) 1997-07-11
DE69836023D1 (de) 2006-11-09
HUP0002622A3 (en) 2002-04-29
AR013157A1 (es) 2000-12-13
ATE340801T1 (de) 2006-10-15
PL337970A1 (en) 2000-09-11
ES2273425T3 (es) 2007-05-01
KR20010021647A (ko) 2001-03-15
ZA985669B (en) 1999-01-11
CY1105805T1 (el) 2011-02-02
HK1026429A1 (en) 2000-12-15
SK183699A3 (en) 2000-07-11
EP1000079B1 (en) 2006-09-27
CZ298110B6 (cs) 2007-06-27
WO1999002542A1 (en) 1999-01-21
IS2439B (is) 2008-11-15
IL133868A0 (en) 2001-04-30
NO329918B1 (no) 2011-01-24
PL192768B1 (pl) 2006-12-29
US6130208A (en) 2000-10-10
BR9810703A (pt) 2000-08-08
EE04119B1 (et) 2003-08-15
UA65576C2 (uk) 2004-04-15
JP4950380B2 (ja) 2012-06-13
NZ502073A (en) 2001-09-28
EP1000079A1 (en) 2000-05-17
HUP0002622A2 (hu) 2001-05-28
TW585764B (en) 2004-05-01
KR100786654B1 (ko) 2007-12-21
SA98190328B1 (ar) 2006-08-15
JP2001509512A (ja) 2001-07-24
CN1864696A (zh) 2006-11-22
SK285766B6 (sk) 2007-07-06
EE200000022A (et) 2000-10-16
MY116421A (en) 2004-01-31
CA2295628C (en) 2008-07-29

Similar Documents

Publication Publication Date Title
CN1263533A (zh) 新型制剂
US20150190469A1 (en) Methods for Forming Compositions for Treating Joints Comprising Bone Morphogenetic Protein and Hyaluronic Acid
RU2733409C2 (ru) Фармацевтические составы, включающие кангрелор высокой чистоты, и способы их получения и применения
CA2256942A1 (en) Human growth hormone-containing aqueous pharmaceutical composition
CN108697717A (zh) 治疗关节的组合物
HU190687B (en) Process for preparing new antithrombotic of polysaccharide base further pharmaceutical compositions containing such substance as active material
PL190493B1 (pl) Kompozycja farmaceutyczna do liofilizacji i jej zastosowanie oraz sposób jej wytwarzania
CA2130762C (en) Treatment of disease and conditions associated with macrophage infiltration
US5767106A (en) Treatment of disease and conditions associated with macrophage infiltration
AU700986B2 (en) Vascular intimal hypasplasia-inhibitory composition
AU2003257524B2 (en) New formulation
HK1026429B (en) New formulation
JP3022915B2 (ja) 癌転移抑制剤
MXPA00000100A (en) New formulation
US6313104B1 (en) Organoprotective solutions
JPS6219531A (ja) 安定なヒト型アンギオテンシン製剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ASTRAZENECA (UK) LIMITED

Free format text: FORMER OWNER: ASTRA PHARMACEUTICALS LTD.

Effective date: 20060616

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20060616

Address after: London, England

Applicant after: Astrazeneca UK Ltd.

Address before: Hertfordshire

Applicant before: British Astra Pharmaceuticals Ltd.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication